KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 1.997 7 days ( -2.19 % )
Last Price $1.87 0.538 %
High/ Low $1.86 - $1.88 5.38%
Chg 7 Days N/A $1.87 $1.87
Chg 30 Days 5.06 % $1.78 $1.87
Chg 12 mos 258.93 % $0.521 $1.87
Trend - 3 mos -31.91 % Width: 234.80 %
Trend - 12 mos 87.01 % Width: 212.06 %
Pred. range - 3 mos $0.506 - $1.69 -72.96 % - -9.48 %
Pred. range - 12 mos $3.36 - $10.47 79.46 % - 460.03 %
Short MA avg 3 mos Sell Apr 16, 2024 - 9 days
Long MA avg 3 mos Buy Apr 17, 2024 - 8 days
Short/Long MA avg 3 mos Buy Apr 19, 2024 - 6 days
Short MA avg 12 mos Sell Apr 16, 2024 - 9 days
Long MA avg 12 mos Sell Feb 08, 2024 - 55 days
Short/Long MA avg 12 mos Sell Feb 21, 2024 - 47 days
Pivot Short Sell Feb 12, 2024 - 53 days
Bollinger Buy Apr 23, 2024 - 4 days
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Synlogic Inc

Synlogic Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed... SYBX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT